Latest Breaking News On - Lidia oostvogels - Page 3 : comparemela.com

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

The randomized, observer blind, placebo-controlled clinical Phase 3 study will include more than 2,500 subjects, 18 years of age and older, who will be randomized into this study out of the non-interventional trial. It complements the recent initiation of CureVacs global pivotal Phase 2b/3 trial, HERALD, for CVnCoV in more than 35,000 participants. The Phase 3 study builds on a non-interventional study on COVID-19 at the University Hospital Mainz involving 3,600 hospital employees, including medicine and dentistry students in their 5 th semester or higher. The study has been ongoing for several months and investigates the distribution (epidemiology) of COVID-19 in a collective of employees of a University Hospital. It focuses on the rate at which SARS-CoV-2-specific antibodies arise and can be detected in hospital employees as well as the frequency of virologically confirmed COVID-19 cases in this cohort of hospital employees.

United statesSarah fakihLidia oostvogelsUniversity hospitalExchange commissionUniversity medical center mainzUniversity hospital mainzUniversity hospital in mainzInfectious diseasesNew york nasdaqVice presidentVice president investorஒன்றுபட்டது மாநிலங்களில்சாரா ஃபேகிபல்கலைக்கழகம் மருத்துவமனைபரிமாற்றம் தரகு

CureVac Launches Specialized Phase 3 Clinical Trial of Coronavirus Vaccine Candidate

Moderna (NASDAQ:MRNA) has now moved into late-stage testing on healthcare workers. CureVac (NASDAQ:CVAC), like BioNTech a clinical-stage biotech based in Europe, announced Monday that its CvnCoV is about to enter phase 3 clinical trials, in testing that involves healthcare workers. The first participant in the study is to be administered the initial shot of the vaccine candidate on Tuesday. Image source: Getty Images. This crucial phase of testing will take place at the University Medical Center Mainz in Germany. It s a randomized, placebo-controlled study with over 2,500 individuals aged 18 and older. CureVac said it compliments the company s phase 2b/3 trial, which involved more than 35,000 people and began last week.

Lidia oostvogelsUniversity medical center mainz

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers - Press Release

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.

United statesSarah fakihLidia oostvogelsUniversity hospitalExchange commissionUniversity medical center mainzUniversity hospital mainzUniversity hospital in mainzInfectious diseasesNew york nasdaqVice presidentVice president investorஒன்றுபட்டது மாநிலங்களில்சாரா ஃபேகிபல்கலைக்கழகம் மருத்துவமனைபரிமாற்றம் தரகு

Investegate |CureVac Announcements | CureVac: CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

- Study builds on observational epidemiological study TÜBINGEN, Germany/ BOSTON, USA - December 21, 2020 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.

United statesSarah fakihLidia oostvogelsUniversity hospitalUniversity medical center mainzUniversity hospital mainzUniversity hospital in mainzInfectious diseasesNew york nasdaqVice presidentVice president investorஒன்றுபட்டது மாநிலங்களில்சாரா ஃபேகிபல்கலைக்கழகம் மருத்துவமனைதொற்று நோய்கள்புதியது யார்க் நாஸ்டாக்

CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers

CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers First participant will be vaccinated on 22 December CureVac is set to launch a new phase 3 study of its COVID-19 vaccine in healthcare workers at the University Medical Center Mainz in Germany. The Tübingen, Germany-headquartered company expects to vaccinate the first participant in this phase 3 study on 22 December 2020. The study will evaluate the safety and efficacy of CureVac’s investigational CVnCoV vaccine, which will be administered as a two-dose regimen. The planned phase 3 study in healthcare workers builds on CureVac’s ongoing non-interventional study, which is investigating the distribution of COVID-19 in employees at University Medical Center Mainz.

Lidia oostvogelsUniversity medical center mainzDrug administrationUniversity medical centerபல்கலைக்கழகம் மருத்துவ மையம்